Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.
Fujimasa Tada,Atsushi Hiraoka,Toshifumi Tada,Masashi Hirooka,Kazuya Kariyama,Joji Tani,Masanori Atsukawa,Koichi Takaguchi,Ei Itobayashi,Shinya Fukunishi,Kunihiko Tsuji,Toru Ishikawa,Kazuto Tajiri,Hironori Ochi,Hidenori Toyoda,Chikara Ogawa,Takashi Nishimura,Takeshi Hatanaka,Satoru Kakizaki,Noritomo Shimada,Kazuhito Kawata,Atsushi Naganuma,Hisashi Kosaka,Tomomitsu Matono,Hidekatsu Kuroda,Yutaka Yata,Hideko Ohama,Kazuhiro Nouso,Asahiro Morishita,Akemi Tsutsui,Takuya Nagano,Norio Itokawa,Tomomi Okubo,Taeang Arai,Keisuke Yokohama,Hiroki Nishikawa,Michitaka Imai,Yohei Koizumi,Shinichiro Nakamura,Hiroko Iijima,Masaki Kaibori,Yoichi Hiasa,Takashi Kumada Journal of gastroenterology（2023）
摘要
Atez/Bev might be an effective therapeutic option in patients with EGV, when appropriate endoscopic treatment for EGV is performed.
更多查看译文
关键词
Atezolizumab plus bevacizumab, Portal hypertension, Hepatocellular carcinoma
AI 理解论文
溯源树
样例
